Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis

Antonio Galvano, Giuseppe Cabibbo, Marco Enea, Calogero Camma', Luca Belli, Giovanni Perricone, Claudio Zavaglia, Andrea Mancuso

Risultato della ricerca: Article

21 Citazioni (Scopus)

Abstract

Background: Data on survival and safety of sorafenib for hepatocellular carcinoma recurrence after liver transplant are still equivocal. Aim: We performed a meta-analysis of published studies, with the aim of estimating the 1-year rates of survival, analysing the variability in survival rates and, finally, identifying the factors associated with a longer survival. Methods: Data from 8 of the 17 selected studies were pooled, while the other 9 were excluded because survival rates were missing. All included studies were retrospective. Results: Overall, the 1-year survival ranged from 18% to 90%. Tumour progression was the main cause of death. The second cause was bleeding, reported only in patients undergoing m-Tor inhibitor therapy. The pooled estimate of 1-year survival was 63%. There was a significant heterogeneity among studies (. P<. 0.0001). Among the 34 variables assessed by univariate meta-regression, 5 were associated with an increase in the 1-year survival rate: (1) male gender (. P=. 0.001); (2) Time to progression (. P=. 0.038); and adverse drug events, divided in (3) gastrointestinal (. P=. 0.038), (4) cardiovascular (. P=. 0.029), and (5) dermatological (. P=. 0.014). Conclusions: Additional data from multicentre prospective studies are required to clearly determine if sorafenib is a safe and acceptable treatment in hepatocellular carcinoma recurrence after liver transplant. Nevertheless, its association with m-Tor inhibitors should be discouraged.
Lingua originaleEnglish
pagine (da-a)324-330
Numero di pagine7
RivistaDigestive and Liver Disease
Volume47
Stato di pubblicazionePublished - 2015

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint Entra nei temi di ricerca di 'Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis'. Insieme formano una fingerprint unica.

  • Cita questo